Mineralys Therapeutics (NASDAQ:MLYS) Posts Quarterly Earnings Results, Misses Estimates By $0.30 EPS

Mineralys Therapeutics (NASDAQ:MLYS) announced its quarterly earnings data on Monday. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.30), Zacks reports. During the same quarter in the prior year, the business earned ($0.57) earnings per share.

Mineralys Therapeutics Price Performance

Shares of MLYS stock traded down $1.54 on Tuesday, reaching $13.38. 397,621 shares of the company were exchanged, compared to its average volume of 179,600. The company has a 50-day moving average of $12.95 and a 200-day moving average of $12.64. The company has a market cap of $665.39 million, a price-to-earnings ratio of -5.51 and a beta of 1.71. Mineralys Therapeutics has a one year low of $5.85 and a one year high of $16.91.

Insider Activity at Mineralys Therapeutics

In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 10,757 shares of the firm’s stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $13.57, for a total value of $145,972.49. Following the completion of the sale, the chief financial officer now owns 236,854 shares of the company’s stock, valued at approximately $3,214,108.78. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction on Friday, October 11th. The stock was sold at an average price of $13.57, for a total value of $145,972.49. Following the transaction, the chief financial officer now directly owns 236,854 shares in the company, valued at $3,214,108.78. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David Malcom Rodman sold 25,482 shares of Mineralys Therapeutics stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $15.03, for a total transaction of $382,994.46. Following the completion of the sale, the insider now directly owns 135,974 shares of the company’s stock, valued at approximately $2,043,689.22. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 51,510 shares of company stock valued at $735,431 in the last three months. Corporate insiders own 33.24% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Mineralys Therapeutics in a research note on Tuesday.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.